Harvard-Broad Genome Editing Technologies Fund

The deadline for the 2021 application cycle has passed. Guidelines from the 2021 competition are posted below for reference but please note, they may change in the next round. The next application deadline is anticipated to be in Fall 2022. Congratulations to the 2021 Harvard-Broad Genome Editing Technologies Fund awardees!

 

Projects funded in 2021:

 

Paola Arlotta, Golub Family Professor of Stem Cell and Regenerative Biology (HSCRB);
and Fei Chen, Assistant Professor of Stem Cell and Regenerative Biology (HSCRB)

“Novel RNA-sensing technologies to probe in vivo cell states in human brain organoids”
 

Ethan Garner, Professor of Molecular and Cellular Biology (MCB)

“A novel method to deliver Cas9 into cells: Endosomal escape meditated by pH actuated pistons within osmotically stable L-Forms”

 

David Liu, Thomas Dudley Cabot Professor of the Natural Sciences (CCB)

“Continuous Evolution of CRISPR-Associated Transposases”

 

David Liu, Thomas Dudley Cabot Professor of the Natural Sciences (CCB)

“Development of a Method for Precise Targeted Gene-Sized Insertions into Mammalian Genomes”

 

David Liu, Thomas Dudley Cabot Professor of the Natural Sciences (CCB)

“Development of Multi-Flap Prime Editing Technologies”

 

David Liu, Thomas Dudley Cabot Professor of the Natural Sciences (CCB)

“Improved Prime Editing Systems Through Illuminating Cellular Determinants of Editing Outcomes”

 

Amy Wagers, Forst Family Professor of Stem Cell and Regenerative Biology (HSCRB)

“Advancing Treatment for Rare Congenital Myopathies by Mutation-Specific In Vivo Genome Editing”

 

Overview

The newly established Harvard-Broad Genome Editing Technologies Fund will support research that improves on existing genome-editing technologies, identifies delivery mechanisms for these technologies, and applies these technologies to the understanding and treatment of rare genetic diseases. As defined by NIH, rare diseases in the United States are those that affect fewer than 200,000 people.[1]
 

Available Funding

Budget requests are not limited. Approximately $2M will be available annually for awards made through this program. This funding can support any expenses related to the cost of performing research over a 15-month project period. Eligible expenses include: research; associated travel costs; the publication and dissemination of findings; and support for undergraduate, graduate and postdoctoral scholars.

Eligibility

Ladder faculty members in Harvard’s Faculty of Arts & Sciences (FAS) and the John A. Paulson School of Engineering & Applied Sciences (SEAS) are eligible to apply. Single- and multi-investigator projects are welcome.

Application Instructions

Applications must be submitted through the Harvard University Funding Portal. To apply, please submit:

1. A one- to two-page proposal (one-inch margins, 11-point font or larger, PDF format) that briefly describes the proposed research project. A one-page appendix with graphics and/or references (optional, PDF format) may be included in addition to the one- to two-page project proposal.

2. Detailed budget for the requested funds (PDF format). There is no prescribed format for the budget request. Faculty are encouraged to work closely with their grant administrators to develop a budget. School assessments and/or indirect costs should not be included in the budget request (these will be accounted for at the time of award). Applicants may request funding to support any expenses related to the cost of performing research over a 15-month project period. The funding period may begin as early as November 1, 2021.

3. Two-page biosketch (PDF format) for the Principal Investigator. In addition, applicants may submit a two-page biosketch for any collaborators involved in the project.

Review Criteria

Proposals will be evaluated on their intellectual merit, innovation, design, feasibility and likely impact on the study of rare diseases.

A small committee of senior faculty members will review submitted proposals. The review committee is made up of:

Steven E. Hyman (Committee Chair), Director of the Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard; core member of the Broad; and Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology

Mark Fishman, Professor in the Harvard Department of Stem Cell and Regenerative Biology; and Chief of the Pathways Clinical Service, Massachusetts General Hospital

Dan Kahne, Higgins Professor of Chemistry and Chemical Biology, Harvard University

Timeline

The initial deadline for receipt of applications was September 17, 2021. Funding decisions will be announced in October 2021. Proposals will be solicited annually by this program.

Questions?

Please contact Jennifer Corby, Research Development Officer (jcorby@fas.harvard.edu) or Susan Gomes, Director of Research Development and Strategy (susan_gomes@harvard.edu) for more information about this program.

 

 

[1] NIH NCATS Genetic and Rare Diseases Information Center, https://rarediseases.info.nih.gov/diseases.